Fertility preservation in young women with endometrial carcinoma; Report of three cases

Tehran University Medical Journal

Volumn 65, Issue 2, 2008, Pages 82-87

  Mousavi, A S ^a   Behtash, N ^a   Karimi Zarchi, M ^a   Modarres Gilani, M ^a   Ghaemmaghami, F ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Conservative management; Endometrial cancer; Infertility

Indexed keywords

GESTAGEN;

ADULT; ARTICLE; CANCER GRADING; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL ARTICLE; ENDOMETRIUM CARCINOMA; FEMALE; FERTILITY PRESERVATION; HUMAN; HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; NULLIGRAVIDA; PATIENT COUNSELING; PHYSICAL EXAMINATION; POSTMENOPAUSE; TRANSVAGINAL ECHOGRAPHY;

EID: 78650321557     PISSN: 16831764     EISSN: 17357322     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hoskins WJ, Perez CA, Young RC. Principals and Practice of Gynecologic Oncology. 3th ed. Philadelphia, PA: Lippincot Williams and wilkins: 2000; p. 981.
2. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984; 64: 417-20.
3. Crissman JD, Azoury RS, Barnes AE, Schellhas HF. Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol 1981; 57: 699-704.
4. Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997; 79: 320-7.
5. Fechner RE, Kaufman RH. Endometrial adenocarcinoma in Stein-Leventhal syndrome. Cancer 1974; 34: 444-52.
6. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110: 1020-7.
7. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214-8.
8. Thornton JG, Brown LA, Wells M, Scott JS. Primary treatment of endometrial cancer with progestagen alone. Lancet 1985; 2: 207-8.
9. Bokhman JV, Chepick OF, Volkova AT, Vishnevsky AS. Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? Gynecol Oncol 1985; 20: 139-55.
10. Niwa K, Morishita S, Hashimoto M, Yokovama Y, Tamaya T, Conservative therapy for endometrial carcinoma in young women treated with curettage and progestron. Int J Clin Oncol 1997: 2: 165-9.
11. Farhi DC, Nosanchuk J, Silverberg SG. Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 1986; 68: 741-5.
12. Kelly RH, Back WH. Progestational agents in the treatment of carcinoma of the Endometrium. N Engl J Med 1961: 264: 216-22.
13. Podratz KC, O'Brien PC, Malkasian GD Jr, Decker DG, Jefferies JA, Edmonson JH. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 1985; 66: 106-10.
14. Saegusa M, Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis. Cancer 1998; 83: 111-21.
15. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004; 95: 133-8.
16. Guido RS, Kanbour-Shakir A, Rulin MC, Christopherson WA. Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer. J Reprod Med 1995; 40: 553-5.
17. Larson DM, Johnson KK, Broste SK, Krawisz BR, Kresl JJ. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol 1995; 86: 38-42.
18. Ong S, Duffy T, Lenehan P, Murphy J. Endometrial pipelle biopsy compared to conventional dilatation and curettage. Ir J Med Sci 1997; 166: 47-9.
19. Bettocchi S, Ceci O, Vicino M, Marello F, Impedovo L, Selvaggi L. Diagnostic inadequacy of dilatation and curettage. Fertil Steril 2001; 75: 803-5.
20. Stock RJ, Kanbour A. Prehysterectomy curettage. Obstet Gynecol 1975; 45: 537-41.
21. Takahashi K, Yoshioka M, Kosuge H, Iizuka Y, Musha T, Yamauchi I, et al. The accuracy of computed tomography and magnetic resonance imaging in evaluating the extent of endometrial carcinoma. Nippon Sanka Fujinka Gakkai Zasshi 1995; 47: 647-54.
22. Varpula MJ, Klemi PJ. Staging of uterine endometrial carcinoma with ultra-low field (0.02 T) MRI: a comparative study with CT. J Comput Assist Tomogr 1993; 17: 641-7.
23. DelMaschio A, Vanzulli A, Sironi S, Spagnolo D, Belloni C, Garancini P, et al. Estimating the depth of myometrial involvement by endometrial carcinoma: efficacy of transvaginal sonography vs MR imaging. AJR Am J Roentgenol 1993; 160: 533-8.
24. Yamashita Y, Mizutani H, Torashima M, Takahashi M, Miyazaki K, Okamura H, et al. Assessment of myometrial invasion by endometrial carcinoma: transvaginal sonography vs contrast-enhanced MR imaging. AJR Am J Roentgenol 1993; 161: 595-9.
25. Zarbo G, Caruso G, Caruso S, Mangano U, Zarbo R. Endometrial cancer: preoperative evaluation of myometrial infiltration magnetic resonance imaging versus transvaginal ultrasonography. Eur J Gynaecol Oncol 2000; 21: 95-7.
26. Kinkel K, Kaji Y, Yu KK, Segal MR, Lu Y, Powell CB, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999; 212: 711-8.
27. Gitsch G, Hanzal E, Jensen D, Hacker NF. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 1995; 85: 504-8.
28. Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 1998; 91: 349-54.
29. Lai CH, Hsueh S, Chao AS, Soong YK. Successful pregnancy after tamoxifen and megestrol acetate therapy for endometrial carcinoma. Br J Obstet Gynaecol 1994; 101: 547-9.
30. Kung FT, Chen WJ, Chou HH, Ko SF, Chang SY. Conservative management of early endometrial adenocarcinoma with repeat curettage and hormone therapy under assistance of hysteroscopy and laparoscopy. Hum Reprod 1997; 12: 1649-53.
31. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997; 90: 434-40.
32. Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 2001; 167: 39-48.
33. Gotlieb WH, Beiner ME, Shalmon B, Korach Y, Segal Y, Zmira N. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 2003; 102: 718-25.
34. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002; 186: 651-7.
35. Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 2005; 97: 924-7.
36. Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 2003; 80: 1315-24.
37. Lowe MP, Cooper BC, Sood AK, Davis WA, Syrop CH, Sorosky JI. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol Oncol 2003; 91: 569-72.
38. Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG 2005; 112: 317-20.